#USA #San Francisco #health research #Alethios #Study Planner

Alethios Launches to Lower the Barriers to Human Health Research

Alethios, a groundbreaking startup, officially announced its launch on October 21, 2025, marking a significant advancement in the field of human health research. Established by CEO Zeenia Framroze in 2023, Alethios aims to democratize health research, which has often faced obstacles such as high costs, lengthy timelines, and limited accessibility.

At the heart of Alethios' innovation is the "Alethios Study Planner," a tool that revolutionizes the way health research is designed and executed. For just $100 per month, this platform facilitates structured, outcomes-based research that is accessible to biotech companies, contract research organizations (CROs), supplement brands, startups, and even citizen scientists. Unlike traditional approaches that may take months or years to execute, Alethios allows researchers to initiate studies quickly, streamlining the entire process from design to participant recruitment.

A New Research Infrastructure

Alethios is designed to empower researchers by providing access to functionality that was previously limited to well-established institutions. The Study Planner allows users to create a decentralized study in a matter of minutes. Researchers can utilize generative AI to kickstart their projects, exploring various study designs based on existing literature and personal preferences.

With the ability to digitize protocols that typically require extensive development time, Alethios shatters the existing norms of clinical research timelines. Jen Murphy from PLT Health Solutions notes, “The Alethios Platform and Study Planner are easy to use and blend ready-to-use tools with options for customization.” This is a game-changer for both seasoned researchers and those new to the field, as it significantly reduces the activation energy needed to launch credible studies.

Once the study design phase is complete, researchers can transition smoothly into the Alethios Study Operator. This tool automates various operational aspects including participant recruitment via the growing Alethiad Participant Community, logistics for study kits, and management of event reporting. Participants also benefit from the platform's consistent updates, helping to maintain high adherence rates—often exceeding 90% in consumer health studies.

Impact and Reach

Alethios has already partnered with numerous organizations within the medical device, biotech, and consumer health sectors. Notable collaborators include Samphire Neuroscience, NextSense, and Aecor.bio, enriching the ecosystem of decentralized human health research. Adam Bohr, co-founder of the postbiotics company Kioga.bio, expressed gratitude for Alethios’ assistance, acknowledging that “the ease and accessibility for participants are massive improvements over academic-styled electronic data captures.” This platform not only enhances recruitment processes but also cultivates a trial population that reflects broader society.

Crawford Currie from Hofseth BioCare stated, “The Alethios platform has transformed our research output. The difference in recruitment efficiency compared to traditional trial centers is stark and tremendously positive.”

Additionally, Alethios has received recognition as a finalist in the 2025 NutraIngredients-USA Startup Award for its impactful role in modernizing research execution in the nutritional health sector. The company is set to participate in educational sessions with industry leaders at events such as SupplySide Global, and will conduct a live study demonstration at the CNS Summit, the premier conference in life sciences.

Conclusion

In summary, Alethios is on a mission to redefine human health research by creating accessible, efficient, and structured study processes. With tools like the Study Planner and Study Operator, researchers now have the resources needed to drive credible health research to a new level, ultimately benefiting a comprehensive array of stakeholders in the human health landscape. As the platform evolves, it promises to remain at the forefront of innovation, paving the way for future advancements in health research accessibility.